Author Login

Correspondence to Author: Maria Isabel Sampaio Tom Back^(1º), Ana Luisa Souto Gandra^(2º), Bernardo Franco de Carvalho Tom Back^(3º), Gabriel Abreu^(4º), Aleida Nazareth Soares^(5º), Frederico Braga Pereira^(6º), Alessandra Hubner de Souza^{(7 º)} 

Faculdade de Ciências Médicas, Brasil.

DOI: 10.52338/joed.2024.4374

Abstract:
Objective: To evaluate the effectiveness intravitreal bevacizumab in the treatment of neovascular macular degeneration (n-AMD) in a real-life scenario.
Method: Retrospective, longitudinal study that evaluated the medical records of 101 eyes (89 patients) with n-AMD who received intravitreal bevacizumab, in a Pro Re Nata (PRN) treatment regimen, between July 2021 and March 2024.
Results: After one year of follow-up, 41 eyes (41.4%) showed improvement in VA, 32 (32.3%) showed a decline in VA, and 26 (26.3%) maintained stable VA. There was a significant reduction in median central macular thickness, with a decrease from 317 µm at baseline to 271 µm (p-value < 0.001; ∆ = 46 µm). Of all variables evaluated, the number of visits was the only modulator significantly correlated with VA improvement (p = 0.008).
Conclusion: In our study, the majority of patients treated with Bevacizumab improved or maintained their CCVA status. Therefore, bevacizumab in a PRN regimen was effective in the treatment of n-AMD, supporting its use in a high-throughput public service. Our study also reinforced the clinical application of OCT-based anatomical results to individualize and optimize therapeutic strategies and protocols for patients

Citation:

Dr. Alessandra Hubner de Souza ,Effectiveness Of Intravitreal Bevacizumab In The Treatment Of Neovascular Age-Related Macular Degeneration: Visual And Anatomical Results - A Real-Life Retrospective Study. Journal of Ophthalmology and Eye Disorders 2025.